CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
dmmr
A collection of 116 issues
Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients
Skip to content
The CRC Digest
◇ RESEARCH
Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients
A prospective multicenter registry enrolled consecutive, unselected patients with primary colorectal adenocarcinoma at six Moscow centers between 2022 and 2025 to establish population-level data on mismatch repair deficiency prevalence
CRC Research Update — August 31, 2026
Today's colorectal cancer research highlights
Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status
Skip to content
The CRC Digest
▸ TREATMENT
Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status
Patients with dMMR/MSI-H tumors who had poor performance status still achieved durable responses to immunotherapy, expanding treatment options for this vulnerable group. (Clinical Colorectal Cancer)
This content
CRC Research Update — August 30, 2026
Today's colorectal cancer research highlights
COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRC
The COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology)
This content
Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer
Skip to content
The CRC Digest
Immunotherapy Combination Achieves Complete Response and Polyp Regression in dMMR Colorectal Cancer
Case report from the NOUS-209-01 trial describes a patient with mismatch repair-deficient colorectal cancer who achieved complete pathologic response and significant colonic polyp regression following treatment with Nous-209 plus pembrolizumab. (Journal of
CRC Research Update — August 28, 2026
Today's colorectal cancer research highlights
Lynch Syndrome Screening Performance Assessed in Early-Onset CRC Cohort
Skip to content
The CRC Digest
◇ RESEARCH
Lynch Syndrome Screening Performance Assessed in Early-Onset CRC Cohort
The Padua study specifically evaluated mismatch repair testing and Lynch syndrome detection in early-onset CRC patients as part of a universal screening approach. (Cancers)
This content is informational only and does not constitute medical
Universal Tumor Screening Evaluated for Lynch Syndrome Detection in 1,022 Consecutive CRC Cases
Skip to content
The CRC Digest
▪ SCREENING
Universal Tumor Screening Evaluated for Lynch Syndrome Detection in 1,022 Consecutive CRC Cases
A University Hospital of Padua study assessed mismatch repair deficiency distribution and Lynch syndrome detection rates across clinical subgroups using immunohistochemistry-based universal tumor screening in consecutive surgical patients. (Cancers)